Since adjuvant therapy is selected according to the biological features of the primary tumor, and as long-term efficacy implies the lack of disease relapse, we assessed whether FN14 and GRP94 predicted the response to adjuvant therapy by evaluating overall survival (Figure 2B). The gene discussed is HSP90B1; the disease is neoplasm.